|
|
|
|
||
Strong Buy
News about SMA Study.If my family member had SMA I would be in the FDA's Face with these results. The alternative is unacceptable. http://finance.yahoo.com/news/ionis-pharmaceuticals-reports-data-nusinersen-153000519.html Key statements; We and Biogen are committed to advancing nusinersen as rapidly as possible. Together we are actively preparing for potential filing and commercial launch of nusinersen. We have completed enrollment in CHERISH, the Phase 3 study in children with SMA and are nearing completion of enrollment in ENDEAR, the Phase 3 study in infants with SMA. This progress places us on track to have data from both of these controlled, Phase 3 studies in the first half of 2017," said B. Lynne Parshall, chief operating officer at Ionis Pharmaceuticals. CC Thursday @ 2:00 EDT |
return to message board, top of board |